Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wobenzym Mechanism of Action in Osteoarthritis
NCT05038410Completed
- Sponsor
- Mucos Pharma
- Start
- Apr 2021
- Primary completion
- Oct 2022
- Modality
- Therapeutic Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Wobenzym in osteoarthritis (OA) (2 arms), sponsored by Mucos Pharma. Primary endpoints: Effects on cartilage biomarkers at 20 weeks, Effects on markers of innate immune response at 20 weeks and 2 more. Started Apr 2021; status: completed.
02
Drugs
Wobenzym
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05038410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038410.